{"id":33546,"date":"2014-10-10T08:39:46","date_gmt":"2014-10-10T12:39:46","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=33546"},"modified":"2014-10-10T08:39:46","modified_gmt":"2014-10-10T12:39:46","slug":"neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546","title":{"rendered":"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/10\/2014 (wallstreetpr) \u2013 <strong>Neuralstem, Inc. (NYSEMKT:CUR)<\/strong> treated its first patient in the initial Phase trial testing NSI-566 human neural stem cells for chronic spinal cord (cSC) trauma.<\/p>\n<p style=\"text-align: justify;\">According to a digital Journal <a href=\"http:\/\/www.digitaljournal.com\/pr\/2247017\" target=\"_blank\">article<\/a>, Neuralstem treated the first cSC injury patient within the first phase trial of the NSI-566 human neural stem cells last week. The treatment was carried out in the UC San Diego School of Medicine, post which the patient was discharged from the hospital.<\/p>\n<p style=\"text-align: justify;\"><strong>Next Steps<\/strong><\/p>\n<p style=\"text-align: justify;\">The first phase trial of the NSI-566 in treating cSCI aims to treat four more patients suffering from thoracic spinal cord trauma (T2-T12). The treatment would mean direct transplant of stem cells into the injury area and would be carried out within a couple of years of injury. All the subjects of the treatment have grade \u2018A\u2019 level of injury, as measured according to the American Spinal Injury Association (AIS) standards. This impairment level signifies that the patient is completely paralyzed with no sensory or motor functions in a specific segment at and below the site of injury.<\/p>\n<p style=\"text-align: justify;\">The trial is being conducted under the guidance of MD, UC San Diego School of Medicine, Joseph Ciacci, who is the principal investigator of the case. He is also a neurosurgeon practitioner at UC San Diego Health System. A significant amount of preclinical work associated with the study was carried out at UC San Diego School of Medicine. The work was conducted by MD, professor in the Department of Anesthesiology, Martin Marsala. He will also lead investigation in another study soon.<\/p>\n<p style=\"text-align: justify;\"><strong>Contribution And Achievement<\/strong><\/p>\n<p style=\"text-align: justify;\">Neuralstem has funded and supported the clinical trial that was conducted at UC San Diego Health System. In this context, the company\u2019s President and CEO, Richard Garr said that Neuralstem has already treated as many as 30 ALS patients successfully. He further added that the present trial marks a significant step for Neuralstem, Inc. (NYSEMKT:CUR).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/10\/2014 (wallstreetpr) \u2013 Neuralstem, Inc. (NYSEMKT:CUR) treated its first patient in the initial Phase trial testing NSI-566 human neural stem cells for chronic [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":33557,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[10636,10635,5377,5378],"stock_ticker":[],"class_list":["post-33546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-joseph-ciacci","tag-martin-marsala","tag-neuralstem-inc-nysemktcur","tag-nysemktcur","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/10\/2014 (wallstreetpr) \u2013 Neuralstem, Inc. (NYSEMKT:CUR) treated its first patient in the initial Phase trial testing NSI-566 human neural stem cells for chronic [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-10T12:39:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"311\" \/>\n\t<meta property=\"og:image:height\" content=\"162\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient\",\"datePublished\":\"2014-10-10T12:39:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg\",\"keywords\":[\"Joseph Ciacci\",\"Martin Marsala\",\"Neuralstem Inc. (NYSEMKT:CUR)\",\"NYSEMKT:CUR\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\",\"name\":\"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg\",\"datePublished\":\"2014-10-10T12:39:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg\",\"width\":311,\"height\":162},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546","og_locale":"en_US","og_type":"article","og_title":"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient - Wall Street PR","og_description":"Boston, MA 10\/10\/2014 (wallstreetpr) \u2013 Neuralstem, Inc. (NYSEMKT:CUR) treated its first patient in the initial Phase trial testing NSI-566 human neural stem cells for chronic [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-10T12:39:46+00:00","og_image":[{"width":311,"height":162,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient","datePublished":"2014-10-10T12:39:46+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg","keywords":["Joseph Ciacci","Martin Marsala","Neuralstem Inc. (NYSEMKT:CUR)","NYSEMKT:CUR"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546","url":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546","name":"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg","datePublished":"2014-10-10T12:39:46+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/index11.jpg","width":311,"height":162},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neuralstem-inc-nysemktcur-conducted-its-first-phase-i-spinal-cord-injury-trial-on-a-patient-33546#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Neuralstem, Inc. (NYSEMKT:CUR) Conducted Its First Phase I Spinal Cord Injury Trial On A Patient"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=33546"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33546\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/33557"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=33546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=33546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=33546"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=33546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}